These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 15075538)

  • 1. Interleukin-2 immunotherapy exerts a differential effect on CD4 and CD8 T cell dynamics.
    Marchetti G; Meroni L; Molteni C; Bandera A; Franzetti F; Galli M; Moroni M; Clerici M; Gori A
    AIDS; 2004 Jan; 18(2):211-6. PubMed ID: 15075538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the impact of highly active antiretroviral therapy on immune recovery in antiretroviral naive patients.
    Al-Harthi L; Voris J; Patterson BK; Becker S; Eron J; Smith KY; D'Amico R; Mildvan D; Snidow J; Pobiner B; Yau L; Landay A
    HIV Med; 2004 Jan; 5(1):55-65. PubMed ID: 14731171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different rates of CD4+ and CD8+ T-cell proliferation in interleukin-2-treated human immunodeficiency virus-positive subjects.
    Caggiari L; Zanussi S; Crepaldi C; Bortolin MT; Caffau C; D'Andrea M; De Paoli P
    Cytometry; 2001 Aug; 46(4):233-7. PubMed ID: 11514956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-2 therapy and thymic production of naive CD4 T cells in HIV-infected patients with severe CD4 lymphopenia.
    Carcelain G; Saint-Mézard P; Altes HK; Tubiana R; Grenot P; Rabian C; de Boer R; Costagliola D; Katlama C; Debré P; Autran B
    AIDS; 2003 Apr; 17(6):841-50. PubMed ID: 12660531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naïve T-cell dynamics in human immunodeficiency virus type 1 infection: effects of highly active antiretroviral therapy provide insights into the mechanisms of naive T-cell depletion.
    Di Mascio M; Sereti I; Matthews LT; Natarajan V; Adelsberger J; Lempicki R; Yoder C; Jones E; Chow C; Metcalf JA; Sidorov IA; Dimitrov DS; Polis MA; Kovacs JA
    J Virol; 2006 Mar; 80(6):2665-74. PubMed ID: 16501076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART.
    Marchetti G; Gori A; Casabianca A; Magnani M; Franzetti F; Clerici M; Perno CF; Monforte Ad; Galli M; Meroni L
    AIDS; 2006 Aug; 20(13):1727-36. PubMed ID: 16931937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-2 therapy restores CD8 cell non-cytotoxic anti-HIV responses in primary infection subjects receiving HAART.
    Martinez-Mariño B; Shiboski S; Hecht FM; Kahn JO; Levy JA
    AIDS; 2004 Oct; 18(15):1991-9. PubMed ID: 15577620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapy.
    Weinberg A; Dickover R; Britto P; Hu C; Patterson-Bartlett J; Kraimer J; Gutzman H; Shearer WT; Rathore M; McKinney R;
    AIDS; 2008 Nov; 22(17):2267-77. PubMed ID: 18981766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamics of T cells and TCR excision circles differ after treatment of acute and chronic HIV infection.
    Lewin SR; Ribeiro RM; Kaufmann GR; Smith D; Zaunders J; Law M; Solomon A; Cameron PU; Cooper D; Perelson AS
    J Immunol; 2002 Oct; 169(8):4657-66. PubMed ID: 12370406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment.
    Marchetti G; Meroni L; Varchetta S; Terzieva V; Bandera A; Manganaro D; Molteni C; Trabattoni D; Fossati S; Clerici M; Galli M; Moroni M; Franzetti F; Gori A
    J Infect Dis; 2002 Sep; 186(5):606-16. PubMed ID: 12195347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological changes in peripheral blood and in lymphoid tissue after treatment of HIV-infected subjects with highly active anti-retroviral therapy (HAART) or HAART + IL-2.
    Zanussi S; Simonelli C; Bortolin MT; D'Andrea M; Crepaldi C; Vaccher E; Nasti G; Politi D; Barzan L; Tirelli U; De Paoli P
    Clin Exp Immunol; 1999 Jun; 116(3):486-92. PubMed ID: 10361239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune reconstitution in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy: a cohort study.
    Johnston AM; Valentine ME; Ottinger J; Baydo R; Gryszowka V; Vavro C; Weinhold K; St Clair M; McKinney RE
    Pediatr Infect Dis J; 2001 Oct; 20(10):941-6. PubMed ID: 11642627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4+ T cell responses to interleukin-2 administration in HIV-infected patients are directly related to the baseline level of immune activation.
    Sereti I; Sklar P; Ramchandani MS; Read SW; Aggarwal V; Imamichi H; Natarajan V; Metcalf JA; Kovacs JA; Tavel J; Davey RT; Dersimonian R; Lane HC
    J Infect Dis; 2007 Sep; 196(5):677-83. PubMed ID: 17674308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of T cell subsets and IL-7 protein expression in HIV-1-infected patients after 7 years HAART.
    Shou C; Weng N; Jin Y; Feng L; Jin C; Hoextermann S; Potthoff A; Skaletz-Rorowski A; Brockmeyer NH; Wu N
    Eur J Med Res; 2011 Nov; 16(11):473-9. PubMed ID: 22027639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymic output during initial highly active antiretroviral therapy (HAART) and during HAART supplementation with interleukin 2 and/or with HIV type 1 immunogen (Remune).
    Pido-Lopez J; Burton C; Hardy G; Pires A; Sullivan A; Gazzard B; Aspinall R; Gotch F; Imami N
    AIDS Res Hum Retroviruses; 2003 Feb; 19(2):103-9. PubMed ID: 12639245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Features of 'CD4-exploders', HIV-positive patients with an optimal immune reconstitution after potent antiretroviral therapy.
    Mussini C; Pinti M; Borghi V; Nasi M; Amorico G; Monterastelli E; Moretti L; Troiano L; Esposito R; Cossarizza A
    AIDS; 2002 Aug; 16(12):1609-16. PubMed ID: 12172082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T cell receptor excision circle (TREC) content following maximum HIV suppression is equivalent in HIV-infected and HIV-uninfected individuals.
    Steffens CM; Smith KY; Landay A; Shott S; Truckenbrod A; Russert M; Al-Harthi L
    AIDS; 2001 Sep; 15(14):1757-64. PubMed ID: 11579236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
    Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
    Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral therapy corrects HIV-1-induced expansion of CD8+ CD45RA+ CD2-) CD11a(bright) activated T cells.
    Yin L; Rodriguez CA; Hou W; Potter O; Caplan MJ; Goodenow MM; Sleasman JW
    J Allergy Clin Immunol; 2008 Jul; 122(1):166-72, 172.e1-2. PubMed ID: 18538835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy.
    Kovacs JA; Vogel S; Metcalf JA; Baseler M; Stevens R; Adelsberger J; Lempicki R; Hengel RL; Sereti I; Lambert L; Dewar RL; Davey RT; Walker RE; Falloon J; Polis MA; Masur H; Lane HC
    Eur J Immunol; 2001 May; 31(5):1351-60. PubMed ID: 11465092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.